FIND CLINICAL TRIALS

 

LAG-3 = LYMPHOCYTE ACTIVATION GENE-3

 
 
 

Incyte is developing an antagonistic anti-LAG-3 antibody.

Lymphocyte activation gene-3 (LAG-3) is a co-inhibitory receptor upregulated on the surfaces of activated CD4+ and CD8+ T cells and other lymphocytes. LAG-3 binds to MHC Class II on antigen-presenting cells with greater affinity than CD4. Signaling through LAG-3 inhibits proliferation and cytokine production in activated effector T cells (T-effs).

In cancer, tumor infiltrating T-effs that become exhausted and dysfunctional through chronic antigenic stimulation may co-express LAG-3 and PD-1. Combined inhibition of the LAG-3 and PD-1 pathways can improve anti-tumor responses by exhausted T-effs in a synergistic manner.

LAG-3 expression on regulatory T cells (T-regs) may also be associated with enhanced T-reg function.

The therapeutic blockade of LAG-3 may strengthen anti-tumor immune responses by restoring activity in exhausted T-effs and inhibiting T-regs.

MOLECULE LIBRARY

image show jak target.image of pi3kδ target.image of fgfr target.image of brd target.image of pim target molecule.image of lsd1 target molecule.image shows ido1 target.image shows arg target.image of pd-1 target molecule. image of gitr target molecule. image of ox40 target molecule.  image of Tim-3 target moleculeimage of Lag-3 target moleculeimage of Axr target molecule